We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 14, 2020

Risk of Early Progression Is Associated With Circulating ESR1 Mutations Under First-Line Anti-Aromatase Treatment in Metastatic Breast Cancer

Breast Cancer Research


Additional Info

Breast Cancer Research
Risk of Early Progression According to Circulating ESR1 Mutation, CA-15.3 and cfDNA Increases Under First-Line Anti-aromatase Treatment in Metastatic Breast Cancer
Breast Cancer Res 2020 May 28;[EPub Ahead of Print], F Clatot, A Perdrix, L Beaussire, J Lequesne, C Lévy, G Emile, M Bubenheim, S Lacaille, C Calbrix, L Augusto, C Guillemet, C Alexandru, M Fontanilles, D Sefrioui, L Burel, S Guénot, D Richard, N Sarafan-Vasseur, F Di Fiore

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading